Clinical Trial Update: IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG [NA]

View source ↗

Summary

The IMPACT-CABG trial evaluating autologous CD133+ stem cell implantation in patients undergoing CABG has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Myocardial Infarction

Drugs mentioned

• Autologous CD133+ stem cell therapy (cell-based therapy for CABG)

Snippet

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Conditions: Myocardial Infarct, Heart Failure | NA | Status: COMPLETED